Imagion Biosystems Launches New PEG-Coated Iron-Oxide Nanoparticles for Life Science Research Applications
ALBUQUERQUE, NEW MEXICO (PRWEB) December 11, 2017 -- Imagion Biosystems Limited (ASX:IBX), a company dedicated to improving healthcare through earlier cancer detection, today announced the commercial launch of PEG-coated nanoparticles as the latest product in its exclusive line of PrecisionMRX® brand nanoparticles.
The new PEG-coated nanoparticles are composed of a polymer-encapsulated 25 nm iron oxide core with a monolayer of methoxypolyethylene glycol (mPEG). This unique coating acts as a steric barrier to protein adsorption, which results in reduced uptake by macrophages, a feature desired by life scientists seeking improved circulation times for in vivo applications such as magnetic particle imaging.
The “stealth” property of the PEG-coated iron oxide nanoparticles has been reported in pre-clinical studies involving the development of MagSense™ superparamagnetic relaxometry technology for earlier cancer detection. Pharmacokinetic data reported at the 2017 World Medical Imaging Congress showed that after 24 hours in circulation, only 10% of injected particles were immobilized in the liver.
Like all PrecisionMRX® brand nanoparticles, the new PEG-coated nanoparticles are manufactured in-house by Imagion Biosystems to ensure narrow size dispersity. Each lot of PrecisionMRX® nanoparticles is thoroughly characterized for particle size, hydrodynamic diameter, and zeta potential. These lot-specific measurements are recorded on a Certificate of Analysis, which is included with every PrecisionMRX® product shipment.
PrecisionMRX® nanoparticles are for research use only. For additional information and current pricing, please visit http://www.imagionbiosystems.com.
About Imagion Biosystems
Imagion Biosystems is at the crossroads of biotechnology and nanotechnology. Its novel bioimaging and nanomagnetic detection systems have been developed specifically to detect cancer and other diseases earlier and with higher specificity than is currently possible. With MagSenseTM technology, the company has the potential to optimize patient care and reduce mortality rates across various cancer indications. Based in Albuquerque, New Mexico, Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.
Matthew Wygant, Imagion Biosystems, http://www.imagionbiosystems.com, +1 408 905 7630, [email protected]
Share this article